Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Analytics

Five things a purity figure cannot tell you

An orthogonal method separates on a different physical principle, so that species co-eluting in the first are likely to resolve in the second. Two runs of the same method at different speeds are not orthogonal.

What the Journal would like to see, and has seen from exactly one laboratory, is a report presenting two chromatograms from two orthogonal separations, stating both figures plainly, and reporting the lower of them as the result. That convention is conservative, it is transparent, and it is slightly commercially uncomfortable for whichever supplier commissioned the work, which is presumably why it has not spread. It is nonetheless the only version of a purity claim that has survived a deliberate attempt to falsify itself, and a claim that has survived such an attempt is a different kind of object from a claim that has never been tested at all.

Equal area is not equal mass

Area per cent contains an assumption that is almost never stated: that each species contributes detector signal in proportion to its mass, at the same rate as the parent. In ultraviolet detection that requires equal absorptivity per unit mass, and peptide impurities frequently do not oblige. A truncated fragment missing several amide bonds absorbs less at two hundred and fourteen nanometres per unit mass than the parent; a fragment missing a tryptophan absorbs dramatically less at two hundred and eighty. An oxidation product may absorb slightly more.

The direction of the resulting error is not fixed, which is what makes it awkward. Where impurities under-respond, area per cent overstates purity. Where they over-respond, it understates it. Regulated pharmaceutical practice addresses this by determining relative response factors for known impurities and applying correction factors, or by using an alternative detection principle with a more nearly uniform response — charged aerosol detection and mass-based approaches both aim at this.

Nothing in this market applies correction factors, and it would be unreasonable to expect it, since doing so requires isolated impurity standards. What is reasonable is that the assumption be visible. A purity figure is an area ratio, area ratios approximate mass ratios, and the approximation has not been quantified for the sample in question. Two sentences on a certificate would say so, and would make the number more useful rather than less.1

Mass spectrometry, and the limits of a matching mass

Electrospray ionisation of a peptide produces multiply charged ions, and the observed mass-to-charge series is deconvoluted to a molecular mass. Agreement with the theoretical mass of the intended sequence, within the accuracy of the instrument, is strong evidence that the molecule has the right elemental composition. It is not evidence that it has the right sequence, because permutations of the same residues have identical mass, and it is not evidence against isomeric degradation, because an isoaspartate rearrangement changes nothing about the mass.

Fragmentation closes most of that gap. Collision-induced dissociation of the peptide backbone produces a ladder of fragment ions whose mass differences read out the sequence, and a full or near-full ladder is genuine sequence confirmation. It requires a tandem instrument, more analyst time and a method that does not use an ionisation-suppressing additive, which is why identity work often runs on a formic acid gradient rather than the trifluoroacetic acid method used for purity.

The practical reading of a certificate follows. Identity confirmed by mass means the elemental composition matches. Identity confirmed by tandem mass spectrometry with sequence coverage means considerably more. Identity confirmed by retention-time comparison means the sample behaves like the standard. Three quite different claims are routinely expressed by the same phrase, and the difference between them is exactly the difference between knowing what is in the vial and knowing that it resembles something.2

Resolution is the joint product of efficiency and selectivity. Improvement in one does not compensate for inadequacy in the other.

On the method trade-off

The second method, and what makes it orthogonal

Orthogonality is not a synonym for repetition. Two runs of the same method differ only in random variation. A shorter and a longer gradient on the same column separate by the same mechanism, and a pair of species co-eluting under one has a good chance of co-eluting under the other. Genuine orthogonality requires a different physical basis for the separation.

For peptides the practical options are well established. Changing mobile-phase pH alters the ionisation state of acidic and basic residues and therefore their effective hydrophobicity, frequently reordering closely eluting species — a peptide method at low pH and the same peptide at neutral pH are substantially different separations. Changing stationary-phase chemistry from octadecyl to phenyl or a polar-embedded phase alters selectivity by mechanism. Hydrophilic interaction chromatography inverts the retention principle. Ion-exchange separates by charge, and capillary electrophoresis by charge-to-size ratio in free solution.

The cost of a second method is instrument time on a sample already in the autosampler, and its value is that it can falsify the first result. Where the two agree, confidence rises substantially. Where they disagree, something is co-eluting and the lower figure is the safer one to report. One laboratory in this market runs two gradients as standard and reports the lower of the two figures; the Journal regards that as the single best analytical practice we have encountered in this trade, and it costs perhaps twenty minutes.3

What each method can and cannot see
QuestionRP-HPLC/UVLC–MSTandem MSSECNitrogen or AAA
Proportion of visible material that is parentYesYesYesPartlyNo
Elemental composition of the main speciesNoYesYesNoNo
SequenceNoNoYes, with coverageNoNo
Isoaspartate isomerOnly if resolvedNoWith specific methodsNoNo
AggregatesNoNoNoYesNo
Counter-ion, water, salt massNoNoNoNoYes, indirectly
Peptide content by massOnly as assay vs standardNoNoNoYes
A matrix of this kind is the honest answer to the question of what a certificate covers. The trade’s standard document consists of the first column only, and the first column contains a No in five of seven rows.

Five things a purity figure cannot tell you

First, how much peptide is in the vial. Counter-ions, residual water, inorganic salts and non-absorbing excipients contribute mass and no chromatographic signal, which is how a preparation can be 99 per cent pure and substantially less than 99 per cent peptide. Purity and content are different quantities and the second is the one that enters any calculation involving a mass.

Second, whether anything is aggregated. Reversed-phase conditions dissociate most non-covalent aggregates before detection, so the monomer is what arrives at the detector. Only a size-based separation reports high molecular weight species.

Third, whether the sequence is correct. Retention-time agreement is consistency; molecular mass is composition; only fragmentation approaches sequence. Fourth, whether an isomeric degradation product is present, since isoaspartate and racemised residues change nothing about mass and may or may not resolve depending on the method. Fifth, anything at all about microbiological quality — bioburden, sterility, endotoxin — which is a separate discipline in a separate laboratory.

Stated as a list it reads like an indictment of the technique, and it is not. Reversed-phase chromatography answers its own question superbly. The list is an indictment of a market that asks it five questions and prints one answer.

A note on method and sourcing

The compendial and regulatory material in this piece is taken from the current general chapters on chromatography and on validation of compendial procedures, from the European Pharmacopoeia chapters on liquid chromatography and on chromatographic separation techniques, and from the harmonised guidelines on analytical validation, on impurities and on specifications for biotechnological products, all read in the original. The separation science is drawn from the chromatography literature, with the peptide-specific behaviour cited where it differs from small-molecule practice.

Where the Journal reports a number it obtained, it states the number of vials, the number of laboratories, whether the vials came from one lot, whether the laboratories knew, and what method parameters were disclosed to us. Where we quote a figure from a certificate we state whether the method was disclosed on it. Where a laboratory or a company answered our questions we distinguish an answer from a refusal and a refusal from a non-response.

Nothing in this department is a recommendation to buy, use or avoid anything. The compounds referred to are sold for research use only and are not approved for human use in any jurisdiction. Corrections and disputes go to standards@compoundjournal.com. Readers with certificates or chromatograms they would like read should write to letters@compoundjournal.com; we do not identify the source of anything sent to us, and we do not publish a reader’s name without permission.

111835628099.312 min / 0.10%98.912 min / 0.05%98.440 min / 0.10%97.540 min / 0.05%per cent
Figure. Purity reported for one physical sample under four method conditions specified by the Journal. Nothing about the material changed between the four bars.

The five-question list in the sidebar is the practical residue of this article. Gradient, wavelength, threshold, standard, second method. A supplier who can answer all five is telling you something real about how the number was made; a supplier who can answer none has sent you a percentage with no procedure behind it, which this department has called a decoration for as long as it has existed.

References

  1. “Relative response factors and the mass-fraction assumption in area-per-cent purity determination.” Analytical Chemistry. 2016;88(9):4589–4597.
  2. “Confirming peptide identity: molecular mass, fragmentation coverage and the limits of retention-time comparison.” Journal of Peptide Science. 2019;25(8):e3195.
  3. “Orthogonal method development for peptide purity determination: pH, phase chemistry and separation mechanism.” Journal of Chromatography A. 2020;1618:460873.

Letters to the Editor

2 printed

Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.

You list five things a purity figure cannot tell you and then say the list is not an indictment of the technique. It reads like one. If a measurement is silent on content, aggregation, sequence, isomers and microbiology, why is it the measurement this market uses at all?

T. Oyelowo, Abeokuta

The Journal replies

Because it is cheap, fast, comparable-looking and genuinely informative about the thing it measures. A tyre pressure gauge is silent on tread depth, brake pads and the driver, and it is still the right instrument for its question. The failure is in a market that owns one gauge and calls the reading roadworthiness.

Acting on your section about system suitability, I asked a laboratory whether the criteria had been met on my run. They sent the suitability summary the same afternoon, unprompted and without charge, and it showed a tailing factor of 1.3 and replicate agreement well inside a per cent. Nothing was being withheld. Nobody had ever asked.

S. Bergqvist, Malmö

Related coverage